A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36).
Bibliographic record
Abstract
TPS8669 Background: Minimally invasive analyses of circulating cell-free tumor DNA (ctDNA) have shown clinical value as an early endpoint of immunotherapy response, allowing patients with primary resistance to be rapidly and accurately identified. In the first of two independent stages, the BR.36 trial demonstrated a sensitivity of ctDNA response for radiographic RECIST response of 82% and a specificity of 75%, with a median time to ctDNA response of 2.1 months. Methods: BR.36 is a multi-center, open-label, biomarker-directed, phase II/III clinical trial of ctDNA molecular response adaptive immuno-chemotherapy in patients with treatment-naïve metastatic NSCLC. The main objective is to evaluate if adding chemotherapy to pembrolizumab for patients who have persistent ctDNA on liquid biopsy after 6 weeks of pembrolizumab, will result in better PFS and OS compared to patients who remain on pembrolizumab until radiographic clinical progression. Key eligibility criteria include: age ≥18 years, ECOG performance status 0-2, metastatic NSCLC, EGFR and ALK mutation negative and PD-L1 Tumor Proportion Score (TPS) ≥ 50%, at least and not more than 2 cycles of the 200 mg or 2 mg/kg IV Q3W dose/schedule of pembrolizumab as first line systemic immunotherapy at the time of screening and RECIST non-PD or clinically stable PD documented prior to enrolment that can continue on immunotherapy if randomized to that arm. The phase II primary endpoint is PFS and has secondary endpoints of feasibility, overall response rate and safety/tolerability. Sex, RECIST response and ECOG status represent stratification criteria. With 110 randomized patients evaluable for progression (55 patients per arm and 71 PFS events observed in this phase of the clinical trial), we would be able to detect a hazard ratio difference of 0.67 with a 1-sided alpha of 0.2 and power of 0.80 using a phase II screening design. The trial will not stop accrual for the phase II analysis of PFS if feasibility endpoints are achieved. In the phase III portion, a total of 210 randomized patients recruited over 3 years and followed for an additional 24 months are required to detect an OS hazard ratio difference of 0.67 with 1-sided alpha of 0.05 and power of 0.8. The total number of events for the final analysis is expected to be 156, and assuming 10% of patients are lost to follow-up, we are targeting 230 patients to be included overall. The primary endpoint of the phase III portion is overall survival, with secondary endpoints of best overall response, response duration, progression-free survival and safety/tolerability. Exploratory endpoints include longitudinal ctDNA analyses by targeted next-generation sequencing and whole genome sequencing approaches. The BR.36 clinical trial is open to enrollment and to date 2 patients have been registered (ClinicalTrials.gov ID: NCT04093167 ). Clinical trial information: NCT04093167 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.001 |
| Meta-epidemiology (narrow) | 0.003 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.005 |
| Insufficient payload (model declined to judge) | 0.004 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".